Business
PAOG To Publish Latest CBD Pharmaceutical Developments Tomorrow, Tuesday April 13, 2021
PAOG To Publish Latest CBD Pharmaceutical Developments Tomorrow, Tuesday April 13, 2021.
About this update from Pao Group, Inc.
[{"type":"text","content":"\n\n\n\nPAOG To Publish Latest CBD Pharmaceutical Developments Tomorrow, Tuesday April 13, 2021\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nPAOG To Publish Latest CBD Pharmaceutical Developments Tomorrow, Tuesday April 13, 2021\nPR Newswire\nSANDUSKY, Ohio, April 12, 2021\n\n\n\nSANDUSKY, Ohio, April 12, 2021 /PRNewswire/ -- PAO Group, Inc. (USOTC: PAOG) today confirmed a management update on the company's ongoing CBD Pharmaceutical Development Program progress scheduled to be released next week on Tuesday, April 13, 2021.\nLast year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled \"METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.\"\nPAOG is working with Veristat, a contract research organization (CRO), dedicated to the clinical advance of therapies and treatments through regulatory approval.   PAOG anticipates soon announcing new breakthroughs in its CBD RespRx pharmaceutical research.  \nLast month, PAOG released a comprehensive update on its CBD Nutraceutical Development Program with the first PAOG CBD Nutraceutical products, packaged by Alkame Holdings, Inc. (USOTC: ALKM), expected to come to market before the end of this year marketed through North American Cannabis Holdings, Inc. (USOTC: USMJ).  Next week, on Tuesday, PAOG will release a similar update on its CBD Pharmaceutical Development Program,\nLearn more about PAOG at www.paogroupinc.com.\nForward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company ...